Glaukos Corp
Company Profile
Business description
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Contact
One Glaukos Way
Aliso ViejoCA92656
USAT: +1 949 367-9600
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
995
Stocks News & Analysis
stocks
Expense concerns for ASX best idea
stocks
Chart of the Week: Australian asset managers face structural pressure
stocks
Going into earnings, is Alphabet a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,171.10 | 72.20 | -0.78% |
| CAC 40 | 8,066.68 | 86.14 | -1.06% |
| DAX 40 | 24,822.79 | 71.65 | -0.29% |
| Dow JONES (US) | 49,015.60 | 12.19 | 0.02% |
| FTSE 100 | 10,154.43 | 53.37 | -0.52% |
| HKSE | 27,763.58 | 63.33 | -0.23% |
| NASDAQ | 23,857.45 | 40.35 | 0.17% |
| Nikkei 225 | 53,255.76 | 102.95 | -0.19% |
| NZX 50 Index | 13,347.40 | 65.47 | -0.49% |
| S&P 500 | 6,978.03 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,866.40 | 56.80 | -0.64% |
| SSE Composite Index | 4,140.18 | 11.05 | -0.27% |